Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study-Reference-Cited by-同舟云学术

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Published:2023-04-03 Issue:4 Volume:62 Page:381-390
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Bilici Ahmet¹^ORCID,Olmez Omer Fatih¹,Kaplan Muhammed Ali²,Oksuzoglu Berna³,Sezer Ahmet⁴,Karadurmus Nuri⁵,Cubukcu Erdem⁶^ORCID,Sendur Mehmet Ali Nahit⁷,Aksoy Sercan⁸,Erdem Dilek⁹,Basaran Gul¹⁰,Cakar Burcu¹¹^ORCID,Shbair Abdallah T. M.¹²,Arslan Cagatay¹³,Sumbul Ahmet Taner⁴,Sezgin Goksu Sema¹⁴^ORCID,Karadag Ibrahim¹⁵,Cicin Irfan¹⁶,Gumus Mahmut¹⁷^ORCID,Selcukbiricik Fatih¹⁸,Harputluoglu Hakan¹⁹,Demirci Umut²⁰

Affiliation:

1. Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey

2. Dicle University Faculty of Medicine, Diyarbakir, Turkey

3. University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey

4. Baskent University Adana Hospital, Adana, Turkey

5. University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey

6. Uludag University Faculty of Medicine, Bursa, Turkey

7. Ankara City Hospital, Ankara, Turkey

8. Hacettepe University Cancer Institute, Ankara, Turkey

9. Samsun Medical Park Hospital, Samsun, Turkey

10. School of Medicine, Acibadem University, Istanbul, Turkey

11. Ege University Faculty of Medicine, Izmir, Turkey